« Back
Home /
Val-Cit-PAB-MMAF (sodium)

Val-Cit-PAB-MMAF (sodium)

Item no.	HY-44177-50mg
Manufacturer	MedChem Express
Amount	50 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Antibodies Primary Antibodies
Type	Antibody Polyclonal
Specific against	other
Purity	98.43
Citations	[1]Svetlana Doronina, et al. Monomethylvaline compounds capable of conjugation to ligands. US20050238649A1.
Smiles	C[C@@H](C(N[C@H](C(O[Na])=O)CC1=CC=CC=C1)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC(C=C3)=CC=C3NC([C@H](CCCNC(N)=O)NC([C@@H](N)C(C)C)=O)=O)=O)=O)=O)=O)OC
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Drug-Linker Conjugates for ADC
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, stored under nitrogen)
Molecular Weight	1159.39
Product Description	Val-Cit-PAB-MMAF sodium is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)[1]
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related
Isoform	Auristatin
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-44177-50mg-safety-datasheet.pdf